On April 28, 2022 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, reported that tumor response and overall survival data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), was accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, VBI Vaccines, APR 28, 2022, View Source [SID1234613153]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
VBI’s data was selected for presentation and discussion in both a poster session and a poster discussion session. The poster discussion will highlight selected abstracts from the poster session, placing the abstracts in context, with a focus on how the findings apply to clinical practice and future research.
Presentation Details
Title: Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a Phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901)
Date: Sunday, June 5, 2022
Poster Session/Poster Discussion Session: Central Nervous System Tumors
Poster Session Time: 8:00 AM – 11:00 AM CDT
Poster Discussion Session Time: 11:30 AM – 1:00 PM CDT
About VBI-1901 and GBM
VBI-1901 is a novel cancer vaccine immunotherapeutic candidate developed using VBI’s enveloped virus-like particle (eVLP) technology to target two highly immunogenic cytomegalovirus (CMV) antigens, gB and pp65. Scientific literature suggests CMV infection is prevalent in multiple solid tumors, including glioblastoma (GBM). GBM is among the most common and aggressive malignant primary brain tumors in humans. In the U.S. alone, 12,000 new cases are diagnosed each year. The current standard of care for treating GBM is surgical resection, followed by radiation and chemotherapy. Even with aggressive treatment, GBM progresses rapidly and has a high mortality.